User menu

Influence of apixaban on commonly used coagulation assays: results from the Belgian national External Quality Assessment Scheme.

Bibliographic reference Van Blerk, M ; Bailleul, E ; Chatelain, Bernard ; Demulder, A ; Devreese, K ; et. al. Influence of apixaban on commonly used coagulation assays: results from the Belgian national External Quality Assessment Scheme.. In: International Journal of Laboratory Hematology, (2017)
Permanent URL http://hdl.handle.net/2078.1/183720
  1. Baglin T., Hillarp A., Tripodi A., Elalamy I., Buller H., Ageno W., Measuring oral direct inhibitors of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis, 10.1111/jth.12149
  2. Kitchen Steve, Gray Elaine, Mackie Ian, Baglin Trevor, Makris Mike, , Measurement of non-Coumarin anticoagulants and their effects on tests of Haemostasis: Guidance from the British Committee for Standards in Haematology, 10.1111/bjh.12975
  3. Van Blerk M., Bailleul E., Chatelain B., Demulder A., Devreese K., Douxfils J., Jochmans K., Mullier F., Wijns W., Soumali M. R., Coucke W., Vernelen K., Van de Walle P., Influence of dabigatran and rivaroxaban on routine coagulation assays : A nationwide Belgian survey, 10.1160/th14-02-0161
  4. EMA Bristol-Myers Squibb/Pfizer: Eliquis ® (apixaban) Summary of Product Characteristics http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf
  5. QUICK ARMAND J., STANLEY-BROWN MARGARET, BANCROFT FREDERIC W., A STUDY OF THE COAGULATION DEFECT IN HEMOPHILIA AND IN JAUNDICE.* : , 10.1097/00000441-193510000-00009
  6. Quick, J Biol Chem, 109, 73 (1935)
  7. Barrett Y. C., Wang Z., Frost C., Shenker A., Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay : , 10.1160/th10-05-0328
  8. Douxfils J., Chatelain C., Chatelain B., Dogné J.-M., Mullier F., Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide : , 10.1160/th12-12-0898
  9. Dale B. J., Ginsberg J. S., Johnston M., Hirsh J., Weitz J. I., Eikelboom J. W., Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents, 10.1111/jth.12720
  10. Douxfils Jonathan, Tamigniau Anne, Chatelain Bernard, Goffinet Catherine, Dogné Jean-Michel, Mullier François, Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays, 10.1186/1477-9560-12-24
  11. Lippi Giuseppe, Favaloro Emmanuel, Laboratory Testing in the Era of Direct or Non–Vitamin K Antagonist Oral Anticoagulants: A Practical Guide to Measuring Their Activity and Avoiding Diagnostic Errors, 10.1055/s-0035-1546827
  12. Gouin-Thibault I., Flaujac C., Delavenne X., Quenet S., Horellou M.-H., Laporte S., Siguret V., Lecompte T., Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays : A multicentre French GEHT study, 10.1160/th13-06-0470
  13. Harenberg J., Du S., Weiss C., Krämer R., Hoppensteadt D., Walenga J., , Report of the Subcommittee on Control of Anticoagulation on the determination of the anticoagulant effects of apixaban: communication from the SSC of the ISTH, 10.1111/jth.12547
  14. Hillarp A., Gustafsson K. M., Faxälv L., Strandberg K., Baghaei F., Fagerberg Blixter I., Berndtsson M., Lindahl T. L., Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays, 10.1111/jth.12649
  15. Lippi Giuseppe, Ardissino Diego, Quintavalla Roberto, Cervellin Gianfranco, Urgent monitoring of direct oral anticoagulants in patients with atrial fibrillation: a tentative approach based on routine laboratory tests, 10.1007/s11239-014-1082-5
  16. Patel Jignesh P., Chitongo Paradzai B., Czuprynska Julia, Roberts Lara N., Patel Raj K., Arya Roopen, Normal prothrombin times in the presence of therapeutic levels of apixaban -in-vivoexperience from King's College Hospital, 10.1111/bjh.13187
  17. Skeppholm Mika, Al-Aieshy Fadiea, Berndtsson Maria, Al-Khalili Faris, Rönquist-Nii Yuko, Söderblom Lisbeth, Östlund Annika Y., Pohanka Anton, Antovic Jovan, Malmström Rickard E., Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation, 10.1016/j.thromres.2015.04.030
  18. Tripodi Armando, Padovan Lidia, Testa Sophie, Legnani Cristina, Chantarangkul Veena, Scalambrino Erica, Ludovici Silvia, Bassi Laura, Peyvandi Flora, How the direct oral anticoagulant apixaban affects hemostatic parameters. Results of a multicenter multiplatform study, 10.1515/cclm-2014-0531
  19. Gosselin R., Grant R. P., Adcock D. M., Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays, 10.1111/ijlh.12528
  20. Samuelson Bethany T., Cuker Adam, Siegal Deborah M., Crowther Mark, Garcia David A., Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants, 10.1016/j.chest.2016.08.1462
  21. Bonar Roslyn, Favaloro Emmanuel J., Mohammed Soma, Ahuja Monica, Pasalic Leonardo, Sioufi John, Marsden Katherine, The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples, 10.1016/j.pathol.2015.11.025
  22. Testa S., Legnani C., Tripodi A., Paoletti O., Pengo V., Abbate R., Bassi L., Carraro P., Cini M., Paniccia R., Poli D., Palareti G., Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study, 10.1111/jth.13486
  23. Levy J. H., Ageno W., Chan N. C., Crowther M., Verhamme P., Weitz J. I., , When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH, 10.1111/jth.13227
  24. Jourdi G., Siguret V., Martin A. C., Golmard J.-L., Godier A., Samama C.-M., Gaussem P., Gouin-Thibault I., Le Bonniec B., Association rate constants rationalise the pharmacodynamics of apixaban and rivaroxaban : , 10.1160/th14-10-0877